临床研究设计准备
OCT的临床研究计划包括全面可行性分析、有效患者招募和持续CRO现场管理。
We've merged Palleos Healthcare to form a wide-reaching European CRO.
Find out more
OCT的临床研究计划包括全面可行性分析、有效患者招募和持续CRO现场管理。
我们充分了解每个项目，深谋远虑和先见之明是研究成功的重要因素。鉴于此，为确保按计划进行交付，优化临床试验设计至关重要。团队有着15年以上的丰富经验，可以预测研究设计开发阶段的多数风险和陷阱。我们的临床试验方法论着眼于达到研究的积极结果。
We never settle for a compromise when choosing between quality, timeline and budget. We always deliver the best with all three. This approach is built on the accumulated experience of our team of professionals and procedures polished over the years.
Irina Petrova, MD
Director of Clinical Operations
每项研究计划开始前，OCT都会进行全面的可行性分析，保证对进行临床试验的可能性进行切实的评估。我们的可行性评估包括以下步骤：全面审查方案和纳入/排除标准、准备可行性问卷、评估患者人群、患者招募技术的开发、分析研究人员和现场经验、检查研究成功所需设备和设施的可用性。
我们深入细致地处理患者招募问题。目标是在规定时间和预算范围内招募符合条件的患者。
对现场进行有效的监测可实现可靠的质量控制。在现场监控期间，OCT的临床监查员（CRA）执行以下任务来监视对药物临床试验质量管理规范（GCP）和本地法规的遵守情况：
此外，我们也充分考量选址因素，规避表现不佳的单位参与研究。
欢迎致电
OCT Clinical is now operating under Palleos Healthcare brand name.
“The merger will undoubtedly create significant synergies, not just doubling but squaring the expertise of both companies”, Philip Räth, Ph.D., managing director at Palleos, said in the release.
“OCT Clinical is proud to join forces with palleos healthcare, as it has an excellent reputation in the industry it serves. Now we can offer tailored solutions to our clients to meet their diverse clinical research needs and accelerate the time of bringing their products to market”, Dmitry Sharov, CEO at OCT Clinical.